Market analysis reports or Roche financial statements

Roche's CT-388 Shows 18.8% Weight Loss in Phase I Trial at 24 Weeks

May 16, 2024, 06:25 AM

Roche has reported positive Phase I results for its dual GLP-1/GIP receptor agonist, CT-388, in people with obesity. The drug demonstrated an 18.8% placebo-adjusted weight loss at 24 weeks, which is faster than the results seen with Wegovy. This promising data comes from a trial size of 96 participants and is part of Roche's $3.1 billion acquisition of Carmot Therapeutics. The news has already impacted Roche's shares positively, with shares trading up.